Suppr超能文献

通过整合人类血浆蛋白质组与基因组来鉴定四种特定部位癌症的潜在药物靶点。

Identification of potential drug targets for four site-specific cancers by integrating human plasma proteome with genome.

作者信息

Yun Zhangjun, Liu Zhu, Sun Ziyi, Yan Xiang, Yang Qianru, Tian Shaodan, Li Xiao, Hou Li

机构信息

Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China; Beijing University of Chinese Medicine, Beijing 100700, China.

Beijing University of Chinese Medicine, Beijing 100700, China.

出版信息

J Pharm Biomed Anal. 2025 Jun 15;258:116731. doi: 10.1016/j.jpba.2025.116731. Epub 2025 Feb 6.

Abstract

Drug targets supported by genetic evidence with a several-fold higher probability of success in clinical trials. We performed a comprehensive proteome-wide Mendelian randomization (MR) analysis to identify causal proteins and potential therapeutic targets for four site-specific cancers. A total of 13,248 protein quantitative trait loci for 4853 plasma proteins were utilized for proteome-wide MR analysis. Identification of cancer causal proteins in the discovery cohort and further validation in the replication cohort. Colocalization, summary-data-based MR (SMR) analysis, and transcriptome‑wide association studies (TWAS) were performed to check the accuracy of the candidate proteins. Two-step MR analysis was used to explore the effects of plasma protein-mediated 248 modifiable factors on cancer. Phenome-wide MR (Phe-MR) analysis, druggability evaluation, and single-cell type expression analysis further assessed the potential of causal proteins. Combining the results of the meta-analysis of MR estimates from the two cohorts, 21, 2, 24 and 1 causal proteins were identified in breast, lung, prostate and stomach cancers, respectively. Evidence from colocalization, SMR analysis, and TWAS highlighted CD36, DNPH1, and PLXND1 as the most promising drug targets for breast cancer, and ZNF175 for prostate cancer. 1 new potential biomarker (PLXND1) for breast cancer, 2 new promising targets (RELL1, DEFB119) for lung cancer, and 8 new circulating biomarkers (ARFIP2, CCN6, CTRB2, HTR7, MRPL33, TNFRSF6B, VAMP5, ZNF175) for prostate cancer were firstly reported. Some plasma proteins may mediate the association of these cancers with other systemic diseases. Additionally, genetically predicted higher BMI and overweight may reduce breast cancer risk by altering CASP8, ADM, PLXND1, TNFRSF9, ULK3 and VSIG4 protein levels. Causal proteins of breast and prostate cancer were expressed predominantly on macrophages in cancerous tissues. This study genetically identified several cancer causal proteins which provided new perspectives for the understanding of the etiology and development of novel targeted drugs for cancer.

摘要

有基因证据支持的药物靶点在临床试验中成功的概率要高出几倍。我们进行了一项全面的全蛋白质组孟德尔随机化(MR)分析,以确定四种特定部位癌症的因果蛋白和潜在治疗靶点。总共利用了4853种血浆蛋白的13248个蛋白质定量性状位点进行全蛋白质组MR分析。在发现队列中鉴定癌症因果蛋白,并在复制队列中进一步验证。进行共定位、基于汇总数据的MR(SMR)分析和全转录组关联研究(TWAS)以检查候选蛋白的准确性。采用两步MR分析来探讨血浆蛋白介导的248种可改变因素对癌症的影响。全表型MR(Phe-MR)分析、药物可及性评估和单细胞类型表达分析进一步评估了因果蛋白的潜力。结合两个队列的MR估计值的荟萃分析结果,分别在乳腺癌、肺癌、前列腺癌和胃癌中鉴定出21、2、24和1种因果蛋白。共定位、SMR分析和TWAS的证据突出了CD36、DNPH1和PLXND1作为乳腺癌最有前景的药物靶点,以及ZNF175作为前列腺癌的药物靶点。首次报道了1种新的乳腺癌潜在生物标志物(PLXND1)、2种新的肺癌有前景靶点(RELL1、DEFB119)和8种新的前列腺癌循环生物标志物(ARFIP2、CCN6、CTRB2、HTR7、MRPL33、TNFRSF6B、VAMP5、ZNF175)。一些血浆蛋白可能介导这些癌症与其他全身性疾病的关联。此外,基因预测的较高BMI和超重可能通过改变CASP8、ADM、PLXND1、TNFRSF9、ULK3和VSIG4蛋白水平来降低乳腺癌风险。乳腺癌和前列腺癌的因果蛋白主要在癌组织中的巨噬细胞上表达。本研究通过基因鉴定了几种癌症因果蛋白,为理解癌症病因和开发新型靶向药物提供了新的视角。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验